Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
MM-302
i
Other names:
MM-302, anti-HER2 antibody conjugated with pegylated liposomal doxorubicin
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
Merrimack
Drug class:
Topoisomerase II inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
‹
doxorubicin hydrochloride (87)
etoposide IV (53)
etoposide oral (33)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
AVA6000 (0)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
SA033 (0)
doxorubicin liposomal (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
ado-trastuzumab emtansine (97)
fam-trastuzumab deruxtecan-nxki (90)
disitamab vedotin (27)
SHR-A1811 (15)
JNJ-0683 (9)
trastuzumab duocarmazine (6)
A166 (6)
PF-06804103 (4)
SBT6050 (4)
BNT323 (4)
BL-M07D1 (3)
XMT-1522 (3)
IKS014 (3)
MRG002 (3)
ZW49 (3)
BB-1701 (2)
ORM-5029 (2)
PRO1102 (2)
XMT-2056 (2)
DP303c (2)
ADC2122 (1)
ALT-P7 (1)
BAT8001 (1)
DAN-311 (1)
DHES0815A (1)
GQ1001 (1)
MEDI4276 (1)
MF-TTZ-MMAE (1)
MYX2449 (1)
TAA013 (1)
(1)
YH012 (1)
BT2111 (1)
ADCT-502 (0)
BAT8010 (0)
DX126-262 (0)
GQ1007 (0)
IBI-354 (0)
JSKN003 (0)
SHR-4602 (0)
(0)
TQB2102 (0)
BI-CON-02 (0)
doxorubicin hydrochloride (87)
etoposide IV (53)
etoposide oral (33)
pegylated liposomal doxorubicin (31)
epirubicin (29)
daunorubicin (20)
cytarabine/daunorubicin liposomal formulation (19)
idarubicin hydrochloride (16)
mitoxantrone (16)
dactinomycin (8)
teniposide (5)
pixantrone (4)
non-pegylated liposomal doxorubicin (3)
pegylated liposomal doxorubicin (1)
IT-141 (1)
SGN-15 (1)
VLS-211 (1)
zoptarelin doxorubicin (1)
RTA 744 (1)
AVA6000 (0)
amsacrine (0)
amrubicin (0)
mitoxantrone liposomal (0)
H-ferritin–nanocaged doxorubicin (0)
HF158K1 (0)
MNPR-202 (0)
non-pegylated liposomal doxorubicin (0)
vosaroxin (0)
amonafide (0)
SQ3370 (0)
THE001 (0)
lyso-thermosensitive liposomal doxorubicin (0)
tirapazamine (0)
idronoxil (0)
INNO-206 (0)
MNPR-201 (0)
NSC311152 (0)
dexrazoxane (0)
SA033 (0)
doxorubicin liposomal (0)
2X-111 (0)
NP-ACT D (0)
valrubicin (0)
ado-trastuzumab emtansine (97)
fam-trastuzumab deruxtecan-nxki (90)
disitamab vedotin (27)
SHR-A1811 (15)
JNJ-0683 (9)
trastuzumab duocarmazine (6)
A166 (6)
PF-06804103 (4)
SBT6050 (4)
BNT323 (4)
BL-M07D1 (3)
XMT-1522 (3)
IKS014 (3)
MRG002 (3)
ZW49 (3)
BB-1701 (2)
ORM-5029 (2)
PRO1102 (2)
XMT-2056 (2)
DP303c (2)
ADC2122 (1)
ALT-P7 (1)
BAT8001 (1)
DAN-311 (1)
DHES0815A (1)
GQ1001 (1)
MEDI4276 (1)
MF-TTZ-MMAE (1)
MYX2449 (1)
TAA013 (1)
(1)
YH012 (1)
BT2111 (1)
ADCT-502 (0)
BAT8010 (0)
DX126-262 (0)
GQ1007 (0)
IBI-354 (0)
JSKN003 (0)
SHR-4602 (0)
(0)
TQB2102 (0)
BI-CON-02 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
MM-302
Sensitive: C2 – Inclusion Criteria
MM-302
Sensitive
:
C2
MM-302
Sensitive: C2 – Inclusion Criteria
MM-302
Sensitive
:
C2
HER-2 positive
HER2 Positive Breast Cancer
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + MM-302
Sensitive: C3 – Early Trials
trastuzumab + MM-302
Sensitive
:
C3
trastuzumab + MM-302
Sensitive: C3 – Early Trials
trastuzumab + MM-302
Sensitive
:
C3
HER-2 overexpression
Gastric Cancer
HER-2 overexpression
Gastric Cancer
trastuzumab + MM-302
Sensitive: D – Preclinical
trastuzumab + MM-302
Sensitive
:
D
trastuzumab + MM-302
Sensitive: D – Preclinical
trastuzumab + MM-302
Sensitive
:
D
HER-2 overexpression
HER2 Positive Breast Cancer
HER-2 overexpression
HER2 Positive Breast Cancer
trastuzumab + MM-302
Sensitive: D – Preclinical
trastuzumab + MM-302
Sensitive
:
D
trastuzumab + MM-302
Sensitive: D – Preclinical
trastuzumab + MM-302
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login